The FTC's complaint against pharmacy benefit managers highlights how these entities manipulate the pricing of essential medications like insulin, driven by rebate incentives rather than patient needs.
Paul Markovich illustrates the broader issue by revealing how he faced resistance from CVS Caremark when trying to introduce a more affordable prostate cancer drug, indicating a systematic problem.
#pharmacy-benefit-managers #insulin-pricing #federal-trade-commission #healthcare-policy #drug-rebates
Collection
[
|
...
]